The Indian phenotype of T2DM patients is associated with clustering of cardiovascular risk factors, increased insulin ...

Consultant in endocrinology and diabetes Professor Vinod Patel discusses current recommended pharmacological treatment ...

Nectar Life Care launches affordable anti-diabetic range to improve accessibility: Our Bureau, Mumbai Tuesday, February 18, 2025, 12:15 Hrs [IST] Nectar Life Care has announced th ...

Kolkata: Prices of 42 medicines, including those used for day-to-day consumption, are likely to change following an order by ...

Researchers found that diabetes remission was achieved in 44% and 28% of patients in the dapagliflozin and placebo groups, respectively, over 12 months. HealthDay News — For patients with overweight ...

Akums combines two potent diabetes medicines for enhanced treatment efficacy: Our Bureau, Bengaluru Tuesday, February 4, 2025, 15:30 Hrs [IST] Akums Drugs and Pharmaceuticals, a l ...

Dapagliflozin plus calorie restriction beneficial for patients with overweight or obesity and type 2 diabetes. (HealthDay News) — For patients with overweight or obesity and type 2 diabetes ...

Diabetes remission was achieved in 44 and 28% of patients in the dapagliflozin and placebo groups, respectively. HealthDay News — For patients with overweight or obesity and type 2 diabetes ...

and were not taking any diabetes medications other than metformin. Scientists randomly assigned participants into two groups — one taking dapagliflozin with a moderate calorie-restricted diet ...

Metformin, a widely used medication for diabetes, helps lower blood sugar by improving how the body uses insulin. Over the years, scientists have explored its potential as a treatment for cancer ...

A common drug used to treat type 2 diabetes can be a “protective agent against non-melanoma skin cancer”, a new study has shown. Researchers have found that people using metformin are less at risk of ...

The results of this cohort study suggest that individuals with type 2 diabetes who initiated treatment with empagliflozin or dapagliflozin had comparable long-term kidney outcomes. These findings ...